Telix has announced the launch of the international NOBLE Registry of its ‘rest of world’ prostate cancer imaging agent and the dosing of the first patient.

Race Oncology (ASX:RAC) has announced the appointment of Dr David Fuller as its chief medical officer.

Australian company Pharmaxis has sold Russian distribution rights to cystic fibrosis therapy BRONCHITOL (mannitol) and completed a $4.4 million placement to institutional investors.

CSL Behring and Cicada Innovations’ new Plasma Protein Purification Challenge seeks to tackle some of the biggest challenges in plasma protein production and to save and improve lives.

Informatics company Alcidion Group (ASX:ALC) has announced its acquisition of UK company ExtraMed, provided an update on its growth and released details of a $17.9 million capital raise.

Adelaide-based Australian biotechnology company Sementis has appointed former AusBiotech CEO and Medicines Australia chair Dr Anna Lavelle as an independent director.

Amplia Therapeutics (ASX:ATX), a company developing new drugs for the treatment for cancer and fibrosis, has announced it has successfully completed the dosing of subjects in its phase one clinical trial of its focal adhesion kinase inhibitor AMP945.

Zelira Therapeutics (ASX:ZLD) says it generated record quarterly product sales and licensing revenues of $225,000 for the March 2021 quarter, up 249 per cent from the previous six months.

An international research team led by Monash University has uncovered a new technique it says could speed up recovery from bone replacements by altering the shape and nucleus of individual stem cells.

AusBiotech united voices across the biotech pipeline as it responded to the University Research Commercialisation consultation and provided views on how any new scheme must be set in the context of a strategic long-term national objective.

AnteoTech (ASX:ADO) has announced it has received CE Mark registration for its EuGeni Reader and the in vitro rapid diagnostic test for the detection of SARS-CoV-2 nucleocapsid antigen, the COVID-19 ART.

The consortium has announced they have received ethics approval for an Australian phase one clinical trial of the COVIGEN COVID-19 vaccine candidate.

Molecular diagnostics company Genetic Technologies (ASX:GTG)  has announced the appointment of Michael Tonroe as its new chief financial officer.